Acadian Asset Management LLC Has $6.63 Million Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Acadian Asset Management LLC reduced its stake in Harvard Bioscience, Inc. (NASDAQ:HBIOGet Rating) by 6.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,067,314 shares of the medical instruments supplier’s stock after selling 70,594 shares during the period. Acadian Asset Management LLC owned 2.59% of Harvard Bioscience worth $6,626,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Essex Investment Management Co. LLC lifted its position in Harvard Bioscience by 8.2% during the fourth quarter. Essex Investment Management Co. LLC now owns 411,875 shares of the medical instruments supplier’s stock worth $2,904,000 after purchasing an additional 31,139 shares during the period. B. Riley Asset Management LLC bought a new stake in Harvard Bioscience during the fourth quarter worth about $4,275,000. Bailard Inc. bought a new stake in Harvard Bioscience during the fourth quarter worth about $104,000. Raymond James & Associates bought a new stake in Harvard Bioscience during the fourth quarter worth about $240,000. Finally, Lake Street Advisors Group LLC bought a new stake in Harvard Bioscience during the first quarter worth about $78,000. 71.44% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HBIO. KeyCorp cut their price objective on shares of Harvard Bioscience from $10.00 to $7.00 and set an “overweight” rating for the company in a research report on Friday, August 5th. TheStreet cut shares of Harvard Bioscience from a “c” rating to a “d+” rating in a research report on Monday, May 23rd.

Insider Activity

In other news, Director Bertrand Loy bought 17,291 shares of the firm’s stock in a transaction on Wednesday, August 24th. The stock was acquired at an average price of $3.23 per share, with a total value of $55,849.93. Following the transaction, the director now owns 382,116 shares of the company’s stock, valued at approximately $1,234,234.68. The acquisition was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Bertrand Loy bought 17,291 shares of the firm’s stock in a transaction on Wednesday, August 24th. The stock was acquired at an average price of $3.23 per share, with a total value of $55,849.93. Following the transaction, the director now owns 382,116 shares of the company’s stock, valued at approximately $1,234,234.68. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO James W. Green bought 40,000 shares of the firm’s stock in a transaction on Wednesday, August 17th. The shares were purchased at an average cost of $3.19 per share, with a total value of $127,600.00. Following the transaction, the chief executive officer now directly owns 2,248,811 shares in the company, valued at approximately $7,173,707.09. The disclosure for this purchase can be found here. Insiders bought 72,651 shares of company stock valued at $234,345 over the last quarter. 6.20% of the stock is owned by company insiders.

Harvard Bioscience Stock Performance

Harvard Bioscience stock opened at $3.22 on Friday. The business has a 50 day moving average of $3.54 and a 200-day moving average of $4.50. Harvard Bioscience, Inc. has a 1 year low of $3.10 and a 1 year high of $8.48. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.42 and a quick ratio of 1.16. The company has a market capitalization of $134.07 million, a P/E ratio of -35.77 and a beta of 1.71.

Harvard Bioscience (NASDAQ:HBIOGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.01. Harvard Bioscience had a positive return on equity of 7.74% and a negative net margin of 3.03%. The company had revenue of $29.21 million during the quarter, compared to the consensus estimate of $30.10 million. On average, equities research analysts predict that Harvard Bioscience, Inc. will post 0.05 earnings per share for the current year.

Harvard Bioscience Profile

(Get Rating)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

Recommended Stories

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.